




PHARMACEUTICAL 2019

ADIAL PHARMACEUTICALS INC.
Rank 316 of 363





PHARMACEUTICAL 2019

ADIAL PHARMACEUTICALS INC. Rank 316 of 363

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 73% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 319% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 198% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	4,693
Cost of Goods Sold	0
Intangible Assets	6.7
Liabilities, Current	258
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,644
Other Revenues	0
Property and Equipment	0
Research and Development	368
Selling, General and Administrative Expense	6,619

Output Variable	Value in 1000 USD
Assets	4,699
Liabilities	258
Expenses	6,987
Revenues	0
Stockholders Equity	4,441
Net Income	-11,631
Comprehensive Net Income	-11,631
Economic Capital Ratio	-161%